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guidelines.
Regarding the preliminary data presented at the
American College of Cardiology 2014 meeting, our data
on VGS were not entirely captured (only ICD9-CM codes
421.0 and 041.00 were used). Furthermore, the VGS IE
diagnosis established by DeSimone et al. (2) raises
serious concern because the VGS does not carry a
unique ICD-9 CM code (unlike staphylococcus, entero-
coccus, and so forth). This etiology was assumed by
including ICD-9 CM code 041.09 or ICD-9 CM code
041.00 (“Streptococcus infection in conditions classi-
ﬁed elsewhere and of unspeciﬁed site, other Strepto-
coccus”) among patients carrying the diagnosis of IE (2).
The accuracy of VGS diagnosis and drawing major
conclusions based on nonspeciﬁc coding can be erro-
neous. Feedback from many experts attending the
American College of Cardiology 2014 meeting helped
us overcome this limitation in our study, resulting
in elimination of VGS group. Hence, our conclusion
“there has been a signiﬁcant rise in the incidence of
streptococcus IE following 2007 guideline” is statisti-
cally sound and the study design valid. Whether the
temporal association noted in our study reﬂects a
causal relationship cannot be deduced from our
study design. We acknowledged this in the limitation
section.
We appreciate the suggestion of DeSimone and
colleagues to look at VGS as a speciﬁc subgroup.
However, as pointed out by Dayer and Thornhill (5),
this has to be done in a randomized controlled design
to eliminate the inherent limitations of a retrospec-
tive database.Sadip Pant, MD
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Presentation on Dual
Antiplatelet Therapy
Duration
Let’s Re-Evaluate Our PrioritiesWe read with interest the paper by Yeh et al. (1)
published in the Journal, reporting on a subgroup
analysis from the DAPT (Dual Antiplatelet Therapy)
trial in which the effect of an extended treatment
with DAPT beyond 1 year was investigated in patients
presenting with or without myocardial infarction
at the time of stent implantation. The authors
concluded that the beneﬁt of an extended treatment
persisted irrespective of the clinical presentation.
We believe the results of this analysis only poorly
support this conclusion for the following motivations.
Reducing mortality is the ultimate goal of cardiovas-
cular medicine. However, the use of combined end-
points, encompassing fatal and nonfatal events, such
as myocardial infarction or cerebrovascular accident,
is necessary to increase study power and limit the
number of patients needed in clinical trials. Death
traditionally comprises a small fraction of such com-
posite outcomes after percutaneous coronary inter-
vention. Therefore, the underlying foundation for
combining fatal and nonfatal outcomes as a reliable
measure of a given treatment effect requires that
nonfatal endpoints are independently associated
with fatal events and that the strength of this asso-
ciation is somewhat comparable across nonfatal
endpoints. The rationale for extending DAPT beyond
the recommended period is to prevent myocardial
infarction, both stent- and nonstent-related, and by
that improving survival.
In contrast, the DAPT study showed an increase in
mortality by an extended course of treatment,
and the subgroup analysis by Yeh et al. (1) strongly
suggests that the excess of fatality originates from
patients presenting without myocardial infarction.
In this patient subset, prolonged DAPT duration was
associated to a 43% mortality increase. However, the
interaction testing for mortality did not reach the
formal level of signiﬁcance (Pint: 0.13). Importantly,
interaction testing is known to be underpowered, and
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1204it greatly increases the risk of incorrectly concluding
that no interaction effect exists when in reality it
does (2). When we calculated the power of detecting
such interaction in the DAPT study as suggested by
Brookes et al. (3) this was roughly as low as 29%.
Misinterpreting such a ﬁnding, which has indeed
a plausible biological explanation (i.e., patients
without prior myocardial infarction are at lower risk
for ischemic recurrences, show lower platelet reac-
tivity, and have potentially higher rate of bleeding
when treated with prolonged antithrombotic therapy)
(4), may expose a large number of patients to un-
necessary bleeding events, which do carry prognostic
implications and may ultimately worsen outcomes.
Deﬁning which subgroups of patients derive a
beneﬁt and which harm from an extended DAPT
regimen is urgent, given the level of uncertainty
clearly voiced by the medical community (5).Francesco Costa, MD
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Dual Antiplatelet Therapy Duration
Let’s Re-Evaluate Our PrioritiesThe DAPT (Dual Antiplatelet Therapy) study showed
reduction in stent thrombosis and myocardialinfarction (MI) and an increase in bleeding with
continued thienopyridine therapy beyond 12 months
after coronary stent treatment (1). In subgroup
analysis (2), continued thienopyridine therapy pro-
vided consistent reductions in ischemic endpoints
irrespective of clinical presentation (MI Group, haz-
ard ratio: 0.27 for stent thrombosis and 0.42 for MI;
No MI Group, hazard ratio: 0.30 for stent thrombosis
and 0.60 for MI). Global Utilization of Streptokinase
moderate or severe bleeding was increased with
continued thienopyridine in both groups (hazard
ratio: 2.38 and 1.53, respectively). The conclusions,
that extended dual antiplatelet therapy reduced
stent thrombosis and MI but increased bleeding
irrespective of clinical presentation, are objectively
supported by the results of this substudy.
The DAPT study was not powered to evaluate the
effect of continued thienopyridine on mortality. We
nevertheless published the MI subgroup data for
mortality to fully acknowledge the importance of this
outcome. However, emphasis on a nonsigniﬁcant,
albeit underpowered, interaction for an individual
component endpoint in a non-pre–speciﬁed analysis
could lead to an erroneous conclusion because of
either type I or type II error. Thus, the ﬁnding,
although notable, should be considered hypothesis-
generating, not conclusive.
Although bleeding is certainly a risk of continued
dual antiplatelet therapy, the difference in mortality
seen in the DAPT study was not, in fact, accounted
for by a difference in antecedent bleeding (1). In
addition, a secondary blinded adjudication using a
sensitive deﬁnition for bleeding-related death did
not support bleeding as the primary reason for the
difference in mortality. Finally, a large comprehen-
sive meta-analysis found no relationship between
extended duration dual antiplatelet therapy and
mortality (3). Subsequent meta-analyses focused only
on drug-eluting stent populations have been driven
by the DAPT study results, and have selectively
excluded studies with populations for whom the
relationship between antiplatelet therapy and mor-
tality, as mediated by bleeding, are applicable (4).
Mortality is undoubtedly a critically important
endpoint in the evaluation of the risks and beneﬁts of
any therapy. We believe that the mortality differ-
ences observed in the DAPT study require careful
attention because of the potential for harm to the
many individuals exposed to this treatment. Howev-
er, the expedient explanation that bleeding explains
the observed mortality differences is not currently
supported by trial data. A disciplined interpretation
